Lyn, Fyn, Syk, BLNK, and PLC-γ2 immunostaining patterns of neoplastic cells in paraffin-embedded biopsies from cases of Hodgkin disease
Case no. . | Lyn . | Fyn . | Syk . | BLNK . | PLC-γ2 . |
|---|---|---|---|---|---|
| Classical Hodgkin disease | |||||
| 1 (NS) | (-) | +/- | - | - | - |
| 2 (NS) | - | (-) | - | - | - |
| 3 (NS) | - | (-) | - | - | - |
| 4 (NS) | - | + | - | - | - |
| 5 (NS) | (-) | + | - | - | - |
| 6 (NS) | - | (-) | - | - | NT |
| 7 (NS) | - | (-) | - | - | - |
| 8 (NS) | -/+ | + | - | - | - |
| 9 (NS) | + | + | - | - | - |
| 10 (NS) | - | - | - | - | NT |
| 11 (NS) | - | + | - | - | - |
| 12 (NS) | - | - | - | - | - |
| 13 (MC) | NT | - | - | NT | - |
| 14 (MC) | - | (-) | - | - | - |
| 15 (MC) | (-) | (-) | - | - | - |
| 16 (MC) | - | -/+ | - | - | - |
| 17 (MC) | + | - | - | - | NT |
| 18 (MC) | - | - | - | - | - |
| 19 (MC) | NT | + | - | - | - |
| 20 (MC) | - | + | - | - | - |
| 21 (MC) | - | - | - | - | - |
| 22 (MC) | - | - | NT | - | - |
| 23 (LR) | - | - | NT | - | - |
| 24 (LR) | - | -/+ | - | - | - |
| 25 (LR) | - | + | - | - | - |
| 26 (LR) | - | - | - | - | - |
| Lymphocyte predominance | |||||
| 1 | + | + | + | + | + |
| 2 | - | + | + | + | + |
| 3 | - | + | + | + | + |
| 4 | - | + | + | + | + |
| 5 | -/+ | + | + | + | + |
| 6 | - | + | + | + | + |
| 7 | + | + | + | + | + |
| 8 | - | + | + | + | + |
| 9 | - | + | NT | + | + |
| 10 | - | + | + | + | + |
| 11 | - | + | + | + | + |
| 12 | - | + | + | (-) | + |
| 13 | - | + | + | + | + |
| 14 | - | + | + | + | + |
| 15 | - | +w | +w | +w | + |
| 16 | - | + | + | +w | + |
| 17 | - | + | + | + | + |
| 18 | + | + | +w | +w | NT |
| 19 | - | + | + | +w | + |
Case no. . | Lyn . | Fyn . | Syk . | BLNK . | PLC-γ2 . |
|---|---|---|---|---|---|
| Classical Hodgkin disease | |||||
| 1 (NS) | (-) | +/- | - | - | - |
| 2 (NS) | - | (-) | - | - | - |
| 3 (NS) | - | (-) | - | - | - |
| 4 (NS) | - | + | - | - | - |
| 5 (NS) | (-) | + | - | - | - |
| 6 (NS) | - | (-) | - | - | NT |
| 7 (NS) | - | (-) | - | - | - |
| 8 (NS) | -/+ | + | - | - | - |
| 9 (NS) | + | + | - | - | - |
| 10 (NS) | - | - | - | - | NT |
| 11 (NS) | - | + | - | - | - |
| 12 (NS) | - | - | - | - | - |
| 13 (MC) | NT | - | - | NT | - |
| 14 (MC) | - | (-) | - | - | - |
| 15 (MC) | (-) | (-) | - | - | - |
| 16 (MC) | - | -/+ | - | - | - |
| 17 (MC) | + | - | - | - | NT |
| 18 (MC) | - | - | - | - | - |
| 19 (MC) | NT | + | - | - | - |
| 20 (MC) | - | + | - | - | - |
| 21 (MC) | - | - | - | - | - |
| 22 (MC) | - | - | NT | - | - |
| 23 (LR) | - | - | NT | - | - |
| 24 (LR) | - | -/+ | - | - | - |
| 25 (LR) | - | + | - | - | - |
| 26 (LR) | - | - | - | - | - |
| Lymphocyte predominance | |||||
| 1 | + | + | + | + | + |
| 2 | - | + | + | + | + |
| 3 | - | + | + | + | + |
| 4 | - | + | + | + | + |
| 5 | -/+ | + | + | + | + |
| 6 | - | + | + | + | + |
| 7 | + | + | + | + | + |
| 8 | - | + | + | + | + |
| 9 | - | + | NT | + | + |
| 10 | - | + | + | + | + |
| 11 | - | + | + | + | + |
| 12 | - | + | + | (-) | + |
| 13 | - | + | + | + | + |
| 14 | - | + | + | + | + |
| 15 | - | +w | +w | +w | + |
| 16 | - | + | + | +w | + |
| 17 | - | + | + | + | + |
| 18 | + | + | +w | +w | NT |
| 19 | - | + | + | +w | + |
NS indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; NT, not tested (material not available); -, all tumor cells negative; (-), staining in single tumor cells up to 3%-5% of the tumor cells; -/+, staining in 30% of the tumor cells; +/-, staining in more than 50% of the tumor cells; +, staining in more than 90% of the tumor cells; w, weak staining.